Skip to content
Company Analysis

Phibro Animal Health Corporatio PAHC

A comprehensive view of key metrics, scores, and financial health for Phibro Animal Health Corporatio

Overview of Phibro Animal Health Corporation

PAHC NGM
Healthcare Drug Manufacturers - Specialty & Generic Framework: Pharma / Mature Biotech Small Cap
Phibro Animal Health Corporation (PAHC), is a Small Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $38.74, about 102.4% undervalued vs fair value, -10.0% 1Y return, placing in the top 25% of its sector.
Metrics P/E 12.9× Rev Growth 17.1% ROE 29.7% Gross Margin 33.8% Div Yield 1.53%
USD 38.74
-0.36%
(Delayed)
• Vol 90d: 30.8%
52-Week Range
Market Cap
$1.57B
Enterprise Value
$2.24B
Overall Score
View breakdown
Overall
Growth
Good
Profitability
Good
Health
Good
Efficiency
Fair
Valuation
Fair
Growth
Good
Profitability
Good
Health
Good
Efficiency
Fair
Valuation
Fair
Completeness: 100%
Confidence: 96%
Updated: Oct 31
Top Beats

Quick Facts

Website https://www.pahc.com
HQ Teaneck, NJ
Employees 2,475
Fiscal year Jun 30

Next Events

Earnings Nov 4 Call: Nov 5

Fair Value Snapshot

Bear Base Bull
$71
$78
$86
Current: $38.74 +102% vs base

Engine Room Money Flow™

Small Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$1.5B
17.1%%
Gross Profit
$512.5M
28.1%%
R&D Expense
$23.7M
-18.7%%
Operating Income (EBIT)
$181.4M
79.2%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
38.0%
Poor

Weak cash conversion - investigate working capital

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$19.5M
197.3% of FCF

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
5
Active Leaks
0/5
Improving
0
High Impact
4
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Phibro Animal Health Corporatio's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
69
/100
Moderate
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • ROIC Sustainably Above Peers ROIC at 90.2th percentile exceeds peers and WACC, demonstrating superior capital allocation.
  • Margins Stable Across Cycles Operating margin volatility is low (stability score 0.96), demonstrating pricing resilience across cycles.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
69
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

vs Industry Peers 100% Coverage
Trade-Off Triangle Visualization A ternary plot showing PAHC's balance between Growth (43.5%), Profitability (33.5%), and Safety (23.1%). Growth 43% Safety 23% Profitability 33%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

78th percentile vs peers
79
Key Signals
Rev Growth YoY 17.1% 77p Revenue CAGR 3Y 15.8% 78p EPS Growth YoY 1.05 81p EPS CAGR 3Y 44.6% 88p TSR 24.8% 60p
Strengths
  • EPS Growth YoY in top 20% of peers (1.05, 81th percentile)
  • EPS CAGR 3Y in top 20% of peers (44.6%, 88th percentile)
  • Superior capital returns - 3 return metrics above peer median
  • Growth above peer median with strong metric coverage (100%)
Risks

No significant risks identified for this axis.

Profitability

60th percentile vs peers
60
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

41th percentile vs peers
42
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Phibro Animal Health Corporatio.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$78.40
- - -
+102.4% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000